UTH.F United Therapeutics Corporation

Healthcare Biotechnology Frankfurt Exchange
532.20 EUR
Close of Nov 13, 2026
388.60 534.20
Market cap
EUR 22.7B
P/E
23.3x
P/B
4.00x
ROE
18.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is UTH.F undervalued?

Graham number
Price532.20
Graham value261.30
Premium103.7%

UTH.F trades 103.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

United Therapeutics Corporation fundamental analysis

No fundamental analysis for United Therapeutics Corporation yet.

United Therapeutics Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish sy…

Full company profile